These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 18680466)
1. Structures of human arylamine N-acetyltransferases. Grant DM Curr Drug Metab; 2008 Jul; 9(6):465-70. PubMed ID: 18680466 [TBL] [Abstract][Full Text] [Related]
2. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2. Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512 [TBL] [Abstract][Full Text] [Related]
3. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. Wu H; Dombrovsky L; Tempel W; Martin F; Loppnau P; Goodfellow GH; Grant DM; Plotnikov AN J Biol Chem; 2007 Oct; 282(41):30189-97. PubMed ID: 17656365 [TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferases: from structure to function. Sim E; Walters K; Boukouvala S Drug Metab Rev; 2008; 40(3):479-510. PubMed ID: 18642144 [TBL] [Abstract][Full Text] [Related]
5. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Goodfellow GH; Dupret JM; Grant DM Biochem J; 2000 May; 348 Pt 1(Pt 1):159-66. PubMed ID: 10794727 [TBL] [Abstract][Full Text] [Related]
6. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012 [TBL] [Abstract][Full Text] [Related]
8. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human. Tsirka T; Boukouvala S; Agianian B; Fakis G Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853 [TBL] [Abstract][Full Text] [Related]
9. NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. Zhang N; Liu L; Liu F; Wagner CR; Hanna PE; Walters KJ J Mol Biol; 2006 Oct; 363(1):188-200. PubMed ID: 16959263 [TBL] [Abstract][Full Text] [Related]
10. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Grant DM; Blum M; Beer M; Meyer UA Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083 [TBL] [Abstract][Full Text] [Related]
11. Arylamine N-acetyltransferases: a structural perspective. Zhou X; Ma Z; Dong D; Wu B Br J Pharmacol; 2013 Jun; 169(4):748-60. PubMed ID: 23517104 [TBL] [Abstract][Full Text] [Related]
12. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies. Wang H; Vath GM; Gleason KJ; Hanna PE; Wagner CR Biochemistry; 2004 Jun; 43(25):8234-46. PubMed ID: 15209520 [TBL] [Abstract][Full Text] [Related]
13. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. Fullam E; Westwood IM; Anderton MC; Lowe ED; Sim E; Noble ME J Mol Biol; 2008 Jan; 375(1):178-91. PubMed ID: 18005984 [TBL] [Abstract][Full Text] [Related]
14. Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad. Kubiak X; Li de la Sierra-Gallay I; Chaffotte AF; Pluvinage B; Weber P; Haouz A; Dupret JM; Rodrigues-Lima F J Biol Chem; 2013 Aug; 288(31):22493-505. PubMed ID: 23770703 [TBL] [Abstract][Full Text] [Related]
16. Crystal structure of arylamine N-acetyltransferases: insights into the mechanisms of action and substrate selectivity. Kubiak X; Dairou J; Dupret JM; Rodrigues-Lima F Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):349-62. PubMed ID: 23289949 [TBL] [Abstract][Full Text] [Related]
17. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines. Liu L; Wagner CR; Hanna PE Chem Res Toxicol; 2009 Dec; 22(12):1962-74. PubMed ID: 19842618 [TBL] [Abstract][Full Text] [Related]
18. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Fretland AJ; Doll MA; Gray K; Feng Y; Hein DW Toxicol Appl Pharmacol; 1997 Feb; 142(2):360-6. PubMed ID: 9070359 [TBL] [Abstract][Full Text] [Related]
19. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Ware JA; Svensson CK Biochem Pharmacol; 1996 Nov; 52(10):1613-20. PubMed ID: 8937477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]